Flow cytometry offers practical advantages for real-time monitoring of CAR T cell expansion, persistence, and toxicity risk in aggressive large B-cell lymphoma patients. Early CAR T cell expansion is ...
SAN DIEGO--(BUSINESS WIRE)--Invivoscribe Inc., a global leader in precision diagnostics and measurable residual disease (MRD) testing, is proud to support CERo Therapeutics Holdings, Inc., an ...
Not all patients respond well to chimeric antigen receptor (CAR) T cell therapies, which reprogram a patient’s own immune cells to recognize and attack cancer. A way to optimize these treatments is to ...
Gold nanoparticles that cluster in response to T cell enzymes can predict cancer immunotherapy success days before tumors ...
Researchers present a new method to safely and preferentially generate CAR T cells directly inside the body using targeted lipid nanoparticles that deliver mRNA directly to T cells. The approach ...
Chimeric antigen receptor (CAR) T-cell therapy has shown efficacy in blood cancers — with six CAR T-cell products now approved by the US Food and Drug Administration (FDA) to treat six hematologic ...
IN8bio announces INB-619, a novel γδ T cell therapy platform targeting CD19, showing promise in B cell depletion with reduced side effects. IN8bio, Inc. has announced the launch of its innovative γδ T ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback